BECTON DICKINSON & CO (BDX)
About BECTON DICKINSON & CO
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $21.8B
- Net income
- $1.7B
- Total assets
- $55.3B
- Market cap
- $43.1B
- Gross margin
- 45.4%
- Operating margin
- 11.8%
- Net margin
- 7.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $21.8B
- Cost of revenue
- $11.9B
- Gross profit
- $9.9B
- Operating expenses
- $7.3B
- Operating income
- $2.6B
- Income tax
- $203.0M
- Net income
- $1.7B
- EPS (basic)
- $5.83
- EPS (diluted)
- $5.82
Balance sheet
- Total assets
- $55.3B
- Current assets
- $9.3B
- Total liabilities
- $29.9B
- Current liabilities
- $8.3B
- Shareholders’ equity
- $25.4B
Cash flow
- Operating cash flow
- $3.4B
- Investing cash flow
- -$818.0M
- Financing cash flow
- -$3.6B
- Net cash flow
- -$1.0B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $43.1B
- P/E ratio
- 32.3
- EPS (diluted)
- $5.82
- Dividend yield
- 2.23%
- Shares outstanding
- 229.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 25, 1963
Becton Dickinson & Co (BDX) Stock Price
- Profitable — net income of $1.7B in FY2025.
- Revenue grew 28% from FY2020 to FY2025.
- Gross margin of 45.4%, net margin 7.7%.
- Trading 10% below its 52-week high.
- Pays a dividend yielding about 2.23% annually.
- Valued at a price-to-earnings (P/E) ratio of 32.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BECTON DICKINSON & CO.
Write a review
News about BECTON DICKINSON & CO
News & sentiment via Polygon.io
Becton Dickinson & Co: frequently asked questions
Is Becton Dickinson & Co an American company?
Yes — Becton Dickinson & Co is an American company headquartered in Franklin Lakes, New Jersey. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.
Where is Becton Dickinson & Co headquartered?
Becton Dickinson & Co is headquartered in Franklin Lakes, New Jersey, United States.
Is Becton Dickinson & Co publicly traded?
Yes — Becton Dickinson & Co is a publicly traded company. Its stock trades under the ticker symbol BDX on the NYSE.
What does Becton Dickinson & Co do?
Becton Dickinson & Co is an American Medical Devices company in the Health & Beauty sector.
